The "ToPIC" Study = Tool to Improve Participation In Clinical Trials
NCT ID: NCT03656276
Last Updated: 2020-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
35 participants
OBSERVATIONAL
2017-03-10
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Adapting and Testing a Novel Self-Compassion Intervention to Reduce Lung Cancer Stigma
NCT06191939
Improving Supportive Care For Patients With Thoracic Malignancies
NCT03216109
Web-based Intervention for Lung Cancer Patients and Their Informal Caregivers
NCT00365963
Effect of Multi-Media Tool on Enrollment in Oncology Clinical Trials
NCT02020252
Evaluating the Communication Between Patients and Providers in Cancer Clinics
NCT06985953
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Oncologists are the intervention population and will be trained in how to use the ToPIC communication tool. Volunteer oncologists will be randomly assigned to immediate training or wait list control. Oncologists who are randomly assigned to the intervention group will receive training, and once they have demonstrated competence with the tool, they will begin using the tool with their patients. Data collection for any patient whom they present treatment options which include a clinical trial will be included for the primary analysis related to recruitment for clinical trials. This collection will begin once the oncologist, regardless of their assigned group, has signed consent and been randomized.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: Oncologists (wait list control)
Oncologists will be wait-listed for training on the Tool to improve Participation In Clinical Trials (ToPIC)
No interventions assigned to this group
Group B: Oncologists (training)
Oncologists will receive immediate training on the Tool to improve Participation In Clinical Trials (ToPIC)
Tool to improve Participation In Clinical Trials (ToPIC)
The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tool to improve Participation In Clinical Trials (ToPIC)
The Tool to improve Participation In Clinical Trials (ToPIC) is a communication tool to facilitate clinical trial decision making conversations between oncologists and patients.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* (Patients)
* Any adults (over age 18)
* Seen in any UW oncology clinic
* Participated in a discussion with a participating oncologist about treatment options that included a therapeutic clinical trial.
Exclusion Criteria
* (Patients) Non-English speaking patients. We exclude non-english speakers due to the unpredictable impacts of the translation/interpreter dynamic and the lack of a pen/paper diagram in the patient's native language. This would include deaf patients.
* Blind patients (or someone who cannot see the pen/paper diagram)
* Those who do not have capacity for decision making.
* Those offered participation in non-therapeutic intent clinical trials. This would include Phase 1 clinical trials due to the non-therapeutic intent.
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
University of Wisconsin, Madison
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Toby Campbell
Role: PRINCIPAL_INVESTIGATOR
University of Wisconsin, Madison
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Wisconsin Carbone Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-1579
Identifier Type: OTHER
Identifier Source: secondary_id
A534260
Identifier Type: OTHER
Identifier Source: secondary_id
SMPH\MEDICINE\HEM-ONC
Identifier Type: OTHER
Identifier Source: secondary_id
UW16060
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.